The authors did also nicely highlight the synergistic effects of TKIs together with anti-CD123 monoclonal antibodies to reduce CML progenitor cells without effecting normal HSPCs [161]. The gene discussed is IL3RA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.